Gateway Bio secures investment from UNIIQ to advance its innovative approach to antimicrobial resistance
Venture Challenge alumnus Gateway Bio, has secured investment from UNIIQ as part of a €2.15 million investment round supporting five innovative startups in South Holland. The investment marks an important milestone for the Leiden-based biotech startup as it moves towards further developing and validating its technology.
Gateway Bio is developing an innovative technology that enables antibiotics to enter bacterial cells, bypassing an important resistance mechanism. With antimicrobial resistance posing an increasing global health challenge, this approach has the potential to contribute to the development of new ways to combat bacterial infections.
The funding will enable Gateway Bio to expand its team with a microbiologist and a chemist, accelerate the further development of its technology and validate its results outside the academic laboratory environment. An important next step will be validation by a pharmaceutical company, bringing the technology closer to potential commercial applications.
As a Venture Challenge alumnus, Gateway Bio is an important part of the LifeSciences@work network. We are proud to see the team take these next steps and continue building on the entrepreneurial journey that started with the support of our community.
Co-founders Mark ter Heide and Jos Paulusse can be seen on the right side of the picture.
Read the original announcement on the UNIIQ website.